Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatectomy | 18 | 2022 | 804 | 2.100 |
Why?
|
Pancreatic Neoplasms | 54 | 2022 | 5263 | 2.020 |
Why?
|
General Surgery | 27 | 2022 | 1636 | 2.010 |
Why?
|
Jejunum | 29 | 2014 | 480 | 1.360 |
Why?
|
Pancreatitis | 27 | 2013 | 1092 | 1.320 |
Why?
|
Hernia, Ventral | 4 | 2020 | 176 | 1.130 |
Why?
|
Internship and Residency | 24 | 2022 | 5791 | 1.130 |
Why?
|
Pancreatitis, Acute Necrotizing | 8 | 2014 | 172 | 1.110 |
Why?
|
Laparoscopy | 13 | 2018 | 2150 | 1.050 |
Why?
|
Pancreaticoduodenectomy | 9 | 2020 | 503 | 1.050 |
Why?
|
Intestine, Small | 19 | 2012 | 1240 | 1.030 |
Why?
|
Education, Medical, Graduate | 8 | 2022 | 2291 | 0.980 |
Why?
|
Sodium-Glucose Transporter 1 | 17 | 2014 | 112 | 0.970 |
Why?
|
Vascular Surgical Procedures | 7 | 2018 | 1476 | 0.910 |
Why?
|
Postoperative Care | 3 | 2016 | 1487 | 0.860 |
Why?
|
Monosaccharide Transport Proteins | 12 | 2005 | 440 | 0.860 |
Why?
|
Intestinal Absorption | 17 | 2011 | 420 | 0.830 |
Why?
|
Sclerotherapy | 2 | 2014 | 175 | 0.820 |
Why?
|
Pancreas | 25 | 2022 | 1687 | 0.790 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 49 | 2021 | 11525 | 0.750 |
Why?
|
Digestive System Surgical Procedures | 4 | 2018 | 576 | 0.730 |
Why?
|
Deoxycytidine | 14 | 2011 | 826 | 0.720 |
Why?
|
Incidental Findings | 2 | 2016 | 689 | 0.720 |
Why?
|
Peptides | 19 | 2005 | 4410 | 0.710 |
Why?
|
Cystadenocarcinoma, Mucinous | 2 | 2015 | 49 | 0.690 |
Why?
|
Operating Rooms | 7 | 2020 | 817 | 0.680 |
Why?
|
Postoperative Complications | 20 | 2020 | 15297 | 0.640 |
Why?
|
Clinical Competence | 11 | 2022 | 4687 | 0.630 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2016 | 1131 | 0.630 |
Why?
|
Intestinal Mucosa | 20 | 2013 | 3037 | 0.630 |
Why?
|
Neoadjuvant Therapy | 13 | 2021 | 2727 | 0.620 |
Why?
|
Gastric Mucosa | 16 | 1989 | 599 | 0.620 |
Why?
|
Dumping Syndrome | 1 | 2016 | 18 | 0.580 |
Why?
|
Gastrointestinal Hormones | 8 | 2004 | 97 | 0.580 |
Why?
|
Phlebotomy | 1 | 2017 | 141 | 0.580 |
Why?
|
Pancreatic Ducts | 7 | 2012 | 328 | 0.570 |
Why?
|
Specialties, Surgical | 6 | 2021 | 391 | 0.570 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2016 | 25 | 0.560 |
Why?
|
Medical Waste | 1 | 2016 | 14 | 0.560 |
Why?
|
Medical Waste Disposal | 1 | 2016 | 12 | 0.560 |
Why?
|
Hospitals | 4 | 2017 | 3954 | 0.560 |
Why?
|
Blood Specimen Collection | 1 | 2017 | 246 | 0.550 |
Why?
|
Ileum | 9 | 2008 | 565 | 0.550 |
Why?
|
Adenocarcinoma | 29 | 2022 | 6364 | 0.550 |
Why?
|
Esophageal Motility Disorders | 1 | 2016 | 44 | 0.540 |
Why?
|
Surgical Mesh | 2 | 2016 | 276 | 0.540 |
Why?
|
Breast Neoplasms | 53 | 2015 | 20824 | 0.540 |
Why?
|
Humans | 333 | 2022 | 744366 | 0.540 |
Why?
|
Hospital Costs | 3 | 2018 | 985 | 0.530 |
Why?
|
Workload | 7 | 2017 | 849 | 0.530 |
Why?
|
Carcinoma, Pancreatic Ductal | 5 | 2021 | 1636 | 0.530 |
Why?
|
Gastric Emptying | 4 | 2016 | 233 | 0.530 |
Why?
|
Certification | 2 | 2018 | 423 | 0.520 |
Why?
|
Adaptation, Physiological | 9 | 2005 | 1312 | 0.520 |
Why?
|
Fluorouracil | 15 | 2011 | 1619 | 0.520 |
Why?
|
Laparotomy | 3 | 2015 | 473 | 0.520 |
Why?
|
Failure to Thrive | 1 | 2016 | 137 | 0.520 |
Why?
|
Gastrointestinal Stromal Tumors | 4 | 2012 | 643 | 0.510 |
Why?
|
Salaries and Fringe Benefits | 1 | 2017 | 264 | 0.510 |
Why?
|
Female | 257 | 2022 | 380193 | 0.500 |
Why?
|
Esophageal and Gastric Varices | 2 | 2016 | 207 | 0.490 |
Why?
|
Dehydration | 1 | 2016 | 233 | 0.490 |
Why?
|
Adrenal Medulla | 1 | 2014 | 58 | 0.480 |
Why?
|
Varicose Ulcer | 1 | 2014 | 52 | 0.480 |
Why?
|
Early Ambulation | 1 | 2014 | 44 | 0.480 |
Why?
|
Catheterization | 3 | 2017 | 1470 | 0.480 |
Why?
|
Male | 205 | 2022 | 350115 | 0.470 |
Why?
|
Denaturing Gradient Gel Electrophoresis | 1 | 2013 | 3 | 0.470 |
Why?
|
Limb Salvage | 1 | 2016 | 433 | 0.470 |
Why?
|
Environmental Health | 1 | 2016 | 278 | 0.460 |
Why?
|
Clodronic Acid | 5 | 1999 | 60 | 0.450 |
Why?
|
Homicide | 1 | 2016 | 287 | 0.440 |
Why?
|
Neuroendocrine Tumors | 2 | 2018 | 594 | 0.440 |
Why?
|
Universities | 1 | 2018 | 951 | 0.430 |
Why?
|
Circadian Rhythm | 11 | 2013 | 2624 | 0.430 |
Why?
|
Pylorus | 2 | 2011 | 86 | 0.430 |
Why?
|
Diabetic Foot | 1 | 2016 | 355 | 0.430 |
Why?
|
Aged | 153 | 2021 | 163288 | 0.420 |
Why?
|
Gallstones | 5 | 2022 | 286 | 0.420 |
Why?
|
Survival Rate | 35 | 2021 | 12788 | 0.420 |
Why?
|
Treatment Outcome | 71 | 2018 | 63107 | 0.420 |
Why?
|
Adenocarcinoma, Mucinous | 2 | 2015 | 507 | 0.410 |
Why?
|
Adrenalectomy | 1 | 2014 | 341 | 0.410 |
Why?
|
Sodium Tetradecyl Sulfate | 1 | 2011 | 14 | 0.400 |
Why?
|
Cholecystectomy, Laparoscopic | 5 | 2015 | 230 | 0.400 |
Why?
|
Pheochromocytoma | 1 | 2014 | 337 | 0.400 |
Why?
|
Peptic Ulcer | 2 | 2012 | 223 | 0.400 |
Why?
|
Cystadenoma, Serous | 1 | 2012 | 102 | 0.390 |
Why?
|
Glucagon-Like Peptides | 9 | 2005 | 127 | 0.390 |
Why?
|
Sclerosing Solutions | 1 | 2011 | 78 | 0.390 |
Why?
|
Antimetabolites, Antineoplastic | 9 | 2010 | 640 | 0.390 |
Why?
|
Middle Aged | 165 | 2021 | 213390 | 0.390 |
Why?
|
Leg | 3 | 2002 | 1116 | 0.380 |
Why?
|
Carcinoma, Papillary | 3 | 2015 | 783 | 0.380 |
Why?
|
Air | 1 | 2011 | 182 | 0.380 |
Why?
|
Gallbladder Neoplasms | 2 | 2010 | 182 | 0.380 |
Why?
|
Work Schedule Tolerance | 4 | 2017 | 563 | 0.370 |
Why?
|
Strongyloidiasis | 1 | 2010 | 27 | 0.370 |
Why?
|
Jejunal Diseases | 1 | 2010 | 50 | 0.360 |
Why?
|
Gastric Bypass | 3 | 2014 | 812 | 0.360 |
Why?
|
Surgical Procedures, Operative | 7 | 2014 | 1877 | 0.350 |
Why?
|
Cell Adhesion Molecules | 10 | 2005 | 1602 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2015 | 9240 | 0.350 |
Why?
|
Cholecystectomy | 6 | 2011 | 395 | 0.350 |
Why?
|
Subliminal Stimulation | 1 | 2009 | 8 | 0.350 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2013 | 954 | 0.350 |
Why?
|
Observer Variation | 1 | 2016 | 2593 | 0.350 |
Why?
|
Duodenal Diseases | 1 | 2010 | 102 | 0.350 |
Why?
|
Schistosomiasis mansoni | 1 | 2010 | 85 | 0.350 |
Why?
|
Varicose Veins | 1 | 2011 | 154 | 0.350 |
Why?
|
Education, Medical | 3 | 2020 | 1722 | 0.340 |
Why?
|
Hernia, Inguinal | 1 | 2011 | 210 | 0.340 |
Why?
|
Patient Care Team | 2 | 2017 | 2531 | 0.340 |
Why?
|
Intestinal Obstruction | 2 | 2012 | 423 | 0.340 |
Why?
|
Diverticulum | 1 | 2010 | 136 | 0.340 |
Why?
|
Costs and Cost Analysis | 4 | 2018 | 1680 | 0.330 |
Why?
|
Adult | 152 | 2020 | 214052 | 0.330 |
Why?
|
Attitude of Health Personnel | 9 | 2021 | 3841 | 0.330 |
Why?
|
Survival Analysis | 40 | 2010 | 10252 | 0.330 |
Why?
|
Prognosis | 52 | 2021 | 29060 | 0.330 |
Why?
|
Tomography, X-Ray Computed | 19 | 2016 | 20130 | 0.320 |
Why?
|
Aged, 80 and over | 60 | 2018 | 57776 | 0.320 |
Why?
|
DNA, Bacterial | 1 | 2013 | 1465 | 0.320 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 740 | 0.320 |
Why?
|
Carcinoid Tumor | 3 | 2006 | 235 | 0.320 |
Why?
|
Mesothelioma | 6 | 2011 | 818 | 0.320 |
Why?
|
Membrane Glycoproteins | 8 | 2004 | 3771 | 0.310 |
Why?
|
Antigens, Neoplasm | 10 | 2005 | 1988 | 0.310 |
Why?
|
Saphenous Vein | 1 | 2011 | 532 | 0.310 |
Why?
|
Carbon Dioxide | 3 | 2011 | 1150 | 0.310 |
Why?
|
Learning | 3 | 2012 | 1711 | 0.300 |
Why?
|
Neoplasm Invasiveness | 10 | 2008 | 3616 | 0.300 |
Why?
|
Electrolytes | 6 | 2001 | 282 | 0.300 |
Why?
|
Regenerative Medicine | 1 | 2011 | 307 | 0.300 |
Why?
|
Societies, Medical | 2 | 2020 | 3743 | 0.300 |
Why?
|
Patient Readmission | 4 | 2018 | 3116 | 0.290 |
Why?
|
Hodgkin Disease | 9 | 2007 | 1415 | 0.290 |
Why?
|
Glucagon-Like Peptide 2 | 8 | 2005 | 50 | 0.290 |
Why?
|
Evidence-Based Medicine | 6 | 2014 | 3611 | 0.290 |
Why?
|
Breast | 3 | 2015 | 1970 | 0.290 |
Why?
|
Personnel Staffing and Scheduling | 5 | 2017 | 500 | 0.280 |
Why?
|
Carotid Stenosis | 1 | 2014 | 854 | 0.280 |
Why?
|
Bacteremia | 1 | 2013 | 963 | 0.280 |
Why?
|
Societies | 1 | 2006 | 104 | 0.280 |
Why?
|
Lung Neoplasms | 18 | 2011 | 13104 | 0.280 |
Why?
|
State Medicine | 2 | 2009 | 217 | 0.280 |
Why?
|
Patient Satisfaction | 2 | 2017 | 3395 | 0.280 |
Why?
|
Epirubicin | 8 | 2010 | 80 | 0.280 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1862 | 0.270 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2011 | 5223 | 0.270 |
Why?
|
Lymphoma, Follicular | 1 | 2010 | 435 | 0.270 |
Why?
|
Education, Medical, Continuing | 4 | 2021 | 840 | 0.270 |
Why?
|
Intestines | 6 | 2008 | 1924 | 0.270 |
Why?
|
Rats | 38 | 2014 | 24252 | 0.270 |
Why?
|
Colon | 10 | 2009 | 1772 | 0.270 |
Why?
|
Brain Neoplasms | 20 | 2011 | 8861 | 0.270 |
Why?
|
Vinblastine | 12 | 2010 | 502 | 0.270 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2011 | 990 | 0.270 |
Why?
|
Job Satisfaction | 2 | 2009 | 534 | 0.270 |
Why?
|
Rats, Sprague-Dawley | 24 | 2014 | 8300 | 0.260 |
Why?
|
Retrospective Studies | 69 | 2022 | 77460 | 0.260 |
Why?
|
Follow-Up Studies | 38 | 2021 | 39052 | 0.260 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 9 | 2008 | 504 | 0.250 |
Why?
|
Cisplatin | 17 | 2009 | 1662 | 0.250 |
Why?
|
Mammaplasty | 1 | 2015 | 1204 | 0.250 |
Why?
|
Time Factors | 44 | 2018 | 40075 | 0.250 |
Why?
|
Decision Support Systems, Clinical | 1 | 2014 | 1164 | 0.250 |
Why?
|
Mitomycin | 11 | 2008 | 259 | 0.250 |
Why?
|
Disease-Free Survival | 20 | 2014 | 6896 | 0.240 |
Why?
|
Dogs | 23 | 2001 | 3912 | 0.240 |
Why?
|
Health Personnel | 2 | 2016 | 3219 | 0.240 |
Why?
|
Ultrasonography, Interventional | 2 | 2011 | 1486 | 0.240 |
Why?
|
Tamoxifen | 7 | 2003 | 981 | 0.240 |
Why?
|
Palliative Care | 11 | 2010 | 3493 | 0.240 |
Why?
|
Neoplasm Staging | 24 | 2018 | 11031 | 0.240 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2018 | 3922 | 0.230 |
Why?
|
Glioma | 11 | 2005 | 3401 | 0.230 |
Why?
|
Risk Assessment | 10 | 2018 | 23336 | 0.230 |
Why?
|
RNA Interference | 9 | 2008 | 2890 | 0.230 |
Why?
|
Physician-Patient Relations | 4 | 2015 | 3229 | 0.230 |
Why?
|
Glucose | 7 | 2011 | 4398 | 0.230 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7282 | 0.230 |
Why?
|
History, 20th Century | 4 | 2018 | 2740 | 0.230 |
Why?
|
Pyloric Antrum | 7 | 1992 | 69 | 0.230 |
Why?
|
Needs Assessment | 3 | 2016 | 1147 | 0.230 |
Why?
|
Carcinoma, Ductal, Breast | 6 | 2009 | 1100 | 0.230 |
Why?
|
Tissue Engineering | 7 | 2011 | 1880 | 0.220 |
Why?
|
Amputation | 1 | 2002 | 3 | 0.220 |
Why?
|
Intestinal Polyps | 2 | 2003 | 100 | 0.220 |
Why?
|
Matrix Metalloproteinase 2 | 5 | 2004 | 472 | 0.220 |
Why?
|
Combined Modality Therapy | 28 | 2009 | 8642 | 0.220 |
Why?
|
Cholecystitis | 3 | 2000 | 182 | 0.220 |
Why?
|
Intestinal Neoplasms | 4 | 2012 | 319 | 0.220 |
Why?
|
Bone Neoplasms | 7 | 2003 | 2530 | 0.210 |
Why?
|
Quality Improvement | 3 | 2021 | 3749 | 0.210 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2002 | 61 | 0.210 |
Why?
|
Analysis of Variance | 17 | 2015 | 6366 | 0.210 |
Why?
|
Healthcare Disparities | 4 | 2022 | 3154 | 0.210 |
Why?
|
Animals | 109 | 2014 | 168768 | 0.210 |
Why?
|
Immunocompromised Host | 2 | 2013 | 847 | 0.210 |
Why?
|
History, 21st Century | 2 | 2018 | 1534 | 0.210 |
Why?
|
Program Development | 2 | 2021 | 1316 | 0.210 |
Why?
|
Recurrence | 12 | 2020 | 8340 | 0.210 |
Why?
|
Ischemia | 4 | 2000 | 1907 | 0.210 |
Why?
|
Cell Division | 16 | 2004 | 4569 | 0.200 |
Why?
|
Carcinoma, Small Cell | 5 | 2006 | 420 | 0.200 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1671 | 0.200 |
Why?
|
Gastroplasty | 2 | 2012 | 142 | 0.200 |
Why?
|
Gastroparesis | 1 | 2003 | 131 | 0.200 |
Why?
|
RNA, Messenger | 21 | 2014 | 13035 | 0.200 |
Why?
|
Race Relations | 1 | 2001 | 39 | 0.190 |
Why?
|
Intussusception | 1 | 2002 | 114 | 0.190 |
Why?
|
Rats, Inbred Lew | 10 | 2008 | 1162 | 0.190 |
Why?
|
Medical Records | 1 | 2006 | 1413 | 0.190 |
Why?
|
Bronchoalveolar Lavage | 1 | 2001 | 120 | 0.190 |
Why?
|
Amiloride | 4 | 1996 | 121 | 0.190 |
Why?
|
Pituitary Neoplasms | 8 | 2006 | 1345 | 0.190 |
Why?
|
Ileostomy | 2 | 1998 | 119 | 0.190 |
Why?
|
Acute Disease | 18 | 2008 | 7147 | 0.190 |
Why?
|
Anthropology, Cultural | 1 | 2001 | 99 | 0.190 |
Why?
|
Colonic Diseases | 1 | 2002 | 202 | 0.190 |
Why?
|
Sodium | 13 | 2002 | 1622 | 0.190 |
Why?
|
Epidermal Growth Factor | 3 | 2001 | 709 | 0.190 |
Why?
|
src-Family Kinases | 6 | 2004 | 551 | 0.180 |
Why?
|
Communication | 4 | 2015 | 3750 | 0.180 |
Why?
|
Ghrelin | 3 | 2013 | 266 | 0.180 |
Why?
|
Bariatric Surgery | 1 | 2010 | 952 | 0.180 |
Why?
|
Oxygen | 2 | 2011 | 4189 | 0.180 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 4 | 2001 | 494 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 8 | 2004 | 2455 | 0.180 |
Why?
|
Gastrointestinal Motility | 2 | 2016 | 225 | 0.180 |
Why?
|
Stomach Neoplasms | 5 | 2010 | 1332 | 0.180 |
Why?
|
Lipoma | 1 | 2002 | 334 | 0.180 |
Why?
|
Mesentery | 1 | 2000 | 205 | 0.170 |
Why?
|
Neoplasms, Second Primary | 3 | 2021 | 1062 | 0.170 |
Why?
|
Interdisciplinary Communication | 2 | 2016 | 950 | 0.170 |
Why?
|
Caco-2 Cells | 5 | 2013 | 387 | 0.170 |
Why?
|
Enteritis | 2 | 2000 | 165 | 0.170 |
Why?
|
England | 5 | 2011 | 522 | 0.170 |
Why?
|
Skull Base Neoplasms | 2 | 2002 | 284 | 0.170 |
Why?
|
Communication Barriers | 2 | 2015 | 398 | 0.170 |
Why?
|
Severity of Illness Index | 6 | 2016 | 15535 | 0.170 |
Why?
|
Sexual Harassment | 1 | 2020 | 79 | 0.170 |
Why?
|
Capsaicin | 2 | 2011 | 232 | 0.170 |
Why?
|
Observation | 1 | 2001 | 312 | 0.170 |
Why?
|
Interleukin-10 | 7 | 2007 | 1200 | 0.170 |
Why?
|
Length of Stay | 12 | 2018 | 6311 | 0.170 |
Why?
|
Stereotyping | 1 | 2001 | 241 | 0.160 |
Why?
|
Postoperative Period | 7 | 2015 | 1842 | 0.160 |
Why?
|
Physicians | 4 | 2021 | 4567 | 0.160 |
Why?
|
Peritoneal Neoplasms | 2 | 2005 | 665 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 12 | 2012 | 3480 | 0.160 |
Why?
|
Electric Stimulation | 1 | 2003 | 1767 | 0.160 |
Why?
|
Genes, erbB-2 | 3 | 2011 | 162 | 0.160 |
Why?
|
Career Choice | 4 | 2018 | 744 | 0.160 |
Why?
|
Intermittent Claudication | 1 | 2000 | 309 | 0.160 |
Why?
|
Analgesia, Epidural | 1 | 2001 | 326 | 0.160 |
Why?
|
Accreditation | 3 | 2017 | 452 | 0.160 |
Why?
|
Angioplasty, Balloon | 2 | 2000 | 653 | 0.160 |
Why?
|
Enterocytes | 4 | 2010 | 225 | 0.150 |
Why?
|
Jejunal Neoplasms | 1 | 1997 | 18 | 0.150 |
Why?
|
Adenoma | 9 | 2006 | 2174 | 0.150 |
Why?
|
Genes, BRCA2 | 3 | 2007 | 618 | 0.150 |
Why?
|
Receptors, Gastrointestinal Hormone | 1 | 1997 | 38 | 0.150 |
Why?
|
Surgical Wound Infection | 2 | 2018 | 1540 | 0.150 |
Why?
|
Competency-Based Education | 2 | 2010 | 211 | 0.150 |
Why?
|
Lymphangioma | 1 | 1997 | 65 | 0.150 |
Why?
|
Analgesics, Non-Narcotic | 2 | 1999 | 366 | 0.150 |
Why?
|
Genes, BRCA1 | 3 | 2007 | 781 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 480 | 0.150 |
Why?
|
Peer Group | 1 | 2022 | 635 | 0.140 |
Why?
|
Extracellular Space | 3 | 1998 | 595 | 0.140 |
Why?
|
Popliteal Artery | 2 | 2000 | 317 | 0.140 |
Why?
|
Databases, Factual | 5 | 2018 | 7730 | 0.140 |
Why?
|
RNA, Small Interfering | 9 | 2005 | 3505 | 0.140 |
Why?
|
Peptide YY | 9 | 1997 | 130 | 0.140 |
Why?
|
Gene Silencing | 5 | 2008 | 1539 | 0.140 |
Why?
|
Educational Measurement | 3 | 2013 | 1210 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 489 | 0.140 |
Why?
|
Regional Blood Flow | 15 | 1999 | 1525 | 0.140 |
Why?
|
Analgesia | 1 | 2001 | 461 | 0.140 |
Why?
|
Antibodies | 1 | 2005 | 2460 | 0.140 |
Why?
|
Medical Staff, Hospital | 3 | 2007 | 601 | 0.140 |
Why?
|
Diagnosis-Related Groups | 1 | 2018 | 455 | 0.140 |
Why?
|
Proctocolectomy, Restorative | 1 | 1998 | 189 | 0.140 |
Why?
|
Femoral Artery | 3 | 2000 | 845 | 0.140 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 1997 | 233 | 0.140 |
Why?
|
Body Water | 2 | 1997 | 343 | 0.140 |
Why?
|
Vagus Nerve | 3 | 2011 | 439 | 0.140 |
Why?
|
Neoplasm Metastasis | 12 | 2018 | 4851 | 0.140 |
Why?
|
Ireland | 3 | 2007 | 161 | 0.140 |
Why?
|
Aspirin | 7 | 2004 | 3283 | 0.140 |
Why?
|
Prospective Studies | 21 | 2017 | 53290 | 0.140 |
Why?
|
Splenic Diseases | 1 | 1997 | 94 | 0.140 |
Why?
|
Ribonucleoside Diphosphate Reductase | 3 | 2004 | 33 | 0.140 |
Why?
|
Cell Membrane Permeability | 2 | 1999 | 590 | 0.140 |
Why?
|
Genetic Testing | 5 | 2010 | 3444 | 0.140 |
Why?
|
GPI-Linked Proteins | 10 | 2005 | 435 | 0.140 |
Why?
|
Safety | 3 | 2020 | 1186 | 0.140 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2009 | 648 | 0.140 |
Why?
|
Drug Utilization | 2 | 2021 | 1183 | 0.130 |
Why?
|
Judgment | 1 | 2018 | 281 | 0.130 |
Why?
|
Aortic Rupture | 1 | 1999 | 312 | 0.130 |
Why?
|
Faculty, Medical | 4 | 2012 | 1181 | 0.130 |
Why?
|
Meningioma | 3 | 2002 | 1209 | 0.130 |
Why?
|
Fundoplication | 2 | 2007 | 138 | 0.130 |
Why?
|
Peptide Biosynthesis | 1 | 1995 | 55 | 0.130 |
Why?
|
Gastrointestinal Tract | 1 | 2022 | 814 | 0.130 |
Why?
|
Colonic Neoplasms | 2 | 2010 | 2542 | 0.130 |
Why?
|
Gene Expression Regulation | 6 | 2012 | 12073 | 0.130 |
Why?
|
Chi-Square Distribution | 5 | 2011 | 3508 | 0.130 |
Why?
|
Water | 6 | 1999 | 1395 | 0.130 |
Why?
|
Hemophilia B | 1 | 2015 | 81 | 0.130 |
Why?
|
Hydrogen-Ion Concentration | 13 | 1999 | 2556 | 0.130 |
Why?
|
Cyclophosphamide | 10 | 2009 | 2242 | 0.130 |
Why?
|
Morbidity | 4 | 2020 | 1768 | 0.130 |
Why?
|
Clinical Clerkship | 2 | 2011 | 532 | 0.130 |
Why?
|
G1 Phase | 2 | 2013 | 415 | 0.130 |
Why?
|
Patient Simulation | 1 | 2017 | 309 | 0.130 |
Why?
|
Sodium Channel Blockers | 1 | 1996 | 176 | 0.130 |
Why?
|
Crohn Disease | 3 | 2013 | 2304 | 0.130 |
Why?
|
Angioplasty, Balloon, Laser-Assisted | 1 | 1994 | 25 | 0.120 |
Why?
|
United States | 19 | 2022 | 69872 | 0.120 |
Why?
|
Cats | 10 | 1999 | 1000 | 0.120 |
Why?
|
Gallbladder | 1 | 1996 | 302 | 0.120 |
Why?
|
Hospital Administration | 1 | 2018 | 353 | 0.120 |
Why?
|
Vagotomy | 2 | 2011 | 83 | 0.120 |
Why?
|
Chlorides | 7 | 2002 | 667 | 0.120 |
Why?
|
Cholelithiasis | 4 | 2003 | 414 | 0.120 |
Why?
|
Efficiency | 2 | 2015 | 462 | 0.120 |
Why?
|
Pancreatic Diseases | 3 | 2008 | 350 | 0.120 |
Why?
|
Esophagogastric Junction | 2 | 2007 | 313 | 0.120 |
Why?
|
Membrane Potentials | 7 | 1989 | 1137 | 0.120 |
Why?
|
Hydrogen | 7 | 2000 | 164 | 0.120 |
Why?
|
Boston | 5 | 2020 | 9312 | 0.120 |
Why?
|
Mitoxantrone | 6 | 2003 | 152 | 0.120 |
Why?
|
Receptor, EphA2 | 2 | 2004 | 42 | 0.120 |
Why?
|
Aortic Aneurysm, Abdominal | 2 | 2006 | 1186 | 0.120 |
Why?
|
Signal Transduction | 7 | 2009 | 23404 | 0.120 |
Why?
|
Hematologic Neoplasms | 2 | 2008 | 1832 | 0.120 |
Why?
|
Quinazolines | 2 | 2011 | 1356 | 0.120 |
Why?
|
Anoikis | 2 | 2004 | 49 | 0.120 |
Why?
|
Forecasting | 2 | 2018 | 2951 | 0.120 |
Why?
|
Lymphoma | 3 | 2001 | 1877 | 0.120 |
Why?
|
Guideline Adherence | 4 | 2021 | 2265 | 0.120 |
Why?
|
Endotoxins | 1 | 1996 | 527 | 0.120 |
Why?
|
Short Bowel Syndrome | 2 | 2012 | 345 | 0.120 |
Why?
|
Language Disorders | 1 | 1995 | 141 | 0.120 |
Why?
|
Workplace | 1 | 2020 | 836 | 0.110 |
Why?
|
Speech Disorders | 1 | 1995 | 189 | 0.110 |
Why?
|
Drug Administration Schedule | 10 | 2010 | 4933 | 0.110 |
Why?
|
Pain, Postoperative | 3 | 2001 | 1643 | 0.110 |
Why?
|
Blotting, Western | 10 | 2012 | 5181 | 0.110 |
Why?
|
Incidence | 8 | 2016 | 20952 | 0.110 |
Why?
|
Stomach | 2 | 1996 | 697 | 0.110 |
Why?
|
Physician Assistants | 1 | 2015 | 192 | 0.110 |
Why?
|
Premenopause | 2 | 2004 | 1033 | 0.110 |
Why?
|
History, 19th Century | 3 | 2008 | 720 | 0.110 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2021 | 980 | 0.110 |
Why?
|
Anemia, Iron-Deficiency | 1 | 1997 | 365 | 0.110 |
Why?
|
Hemostatics | 1 | 2015 | 229 | 0.110 |
Why?
|
Diagnosis, Differential | 6 | 2014 | 12961 | 0.110 |
Why?
|
E-Box Elements | 1 | 2012 | 21 | 0.110 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1996 | 386 | 0.110 |
Why?
|
Receptors, Estrogen | 4 | 2011 | 2190 | 0.110 |
Why?
|
S Phase | 1 | 2013 | 423 | 0.110 |
Why?
|
Anti-Bacterial Agents | 4 | 2021 | 7182 | 0.110 |
Why?
|
Fasciitis, Necrotizing | 1 | 2013 | 79 | 0.110 |
Why?
|
Stroke | 2 | 2014 | 9981 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 6 | 2013 | 2504 | 0.110 |
Why?
|
Chronobiology Disorders | 1 | 2013 | 74 | 0.110 |
Why?
|
Burnout, Professional | 1 | 2021 | 694 | 0.110 |
Why?
|
Obesity | 4 | 2013 | 12746 | 0.110 |
Why?
|
Arterial Occlusive Diseases | 2 | 1994 | 793 | 0.110 |
Why?
|
Hemophilia A | 1 | 2015 | 351 | 0.100 |
Why?
|
Research | 1 | 2001 | 1999 | 0.100 |
Why?
|
Biological Transport | 3 | 2010 | 2120 | 0.100 |
Why?
|
Boidae | 2 | 2002 | 15 | 0.100 |
Why?
|
Sphincterotomy, Endoscopic | 1 | 1991 | 41 | 0.100 |
Why?
|
Decision Making | 5 | 2011 | 3888 | 0.100 |
Why?
|
Vincristine | 6 | 1999 | 1039 | 0.100 |
Why?
|
Carcinoma, Lobular | 2 | 2009 | 484 | 0.100 |
Why?
|
Genetic Counseling | 2 | 2010 | 600 | 0.100 |
Why?
|
Multivariate Analysis | 14 | 2014 | 12244 | 0.100 |
Why?
|
Colectomy | 3 | 2006 | 680 | 0.100 |
Why?
|
Hematoma | 1 | 1997 | 758 | 0.100 |
Why?
|
Period Circadian Proteins | 1 | 2012 | 102 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 5534 | 0.100 |
Why?
|
Apoptosis | 12 | 2012 | 9724 | 0.100 |
Why?
|
Esophageal Neoplasms | 3 | 2010 | 1585 | 0.100 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1637 | 0.100 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 1 | 2012 | 101 | 0.100 |
Why?
|
Risk Factors | 18 | 2020 | 72296 | 0.100 |
Why?
|
Alanine Transaminase | 2 | 2012 | 592 | 0.100 |
Why?
|
Soft Tissue Infections | 1 | 2013 | 155 | 0.100 |
Why?
|
Caspases | 8 | 2006 | 928 | 0.100 |
Why?
|
Preoperative Care | 3 | 2015 | 2251 | 0.100 |
Why?
|
Specialization | 1 | 2016 | 776 | 0.090 |
Why?
|
Radiotherapy, Conformal | 2 | 2006 | 548 | 0.090 |
Why?
|
Lung Diseases | 1 | 2001 | 1887 | 0.090 |
Why?
|
Cholecystokinin | 3 | 1996 | 114 | 0.090 |
Why?
|
Plagiarism | 1 | 2010 | 22 | 0.090 |
Why?
|
Glucose Transporter Type 2 | 3 | 2005 | 62 | 0.090 |
Why?
|
Afferent Pathways | 1 | 2011 | 302 | 0.090 |
Why?
|
Dacarbazine | 2 | 2005 | 566 | 0.090 |
Why?
|
Curriculum | 2 | 2018 | 3605 | 0.090 |
Why?
|
Chronic Disease | 11 | 2014 | 9145 | 0.090 |
Why?
|
Young Adult | 9 | 2018 | 56429 | 0.090 |
Why?
|
Vascular Diseases | 1 | 1999 | 1161 | 0.090 |
Why?
|
Strongyloides stercoralis | 1 | 2010 | 23 | 0.090 |
Why?
|
Estrogen Antagonists | 2 | 2003 | 152 | 0.090 |
Why?
|
Thrombophlebitis | 1 | 2011 | 309 | 0.090 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2011 | 205 | 0.090 |
Why?
|
Intestinal Diseases | 2 | 2010 | 530 | 0.090 |
Why?
|
Lymphatic Metastasis | 6 | 2018 | 2924 | 0.090 |
Why?
|
Veterans Health | 2 | 2022 | 216 | 0.090 |
Why?
|
Ethanol | 5 | 1998 | 1342 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2006 | 1524 | 0.090 |
Why?
|
Data Collection | 3 | 2011 | 3339 | 0.090 |
Why?
|
Bioengineering | 1 | 2011 | 99 | 0.090 |
Why?
|
Pleural Neoplasms | 2 | 2005 | 607 | 0.090 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2009 | 14 | 0.090 |
Why?
|
Centralized Hospital Services | 1 | 2009 | 18 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2013 | 2938 | 0.090 |
Why?
|
Methotrexate | 9 | 2003 | 1728 | 0.090 |
Why?
|
Drug Chronotherapy | 1 | 2009 | 10 | 0.090 |
Why?
|
Ultrasonography | 5 | 2014 | 5984 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2021 | 1796 | 0.090 |
Why?
|
Doxorubicin | 7 | 2009 | 2234 | 0.090 |
Why?
|
Patient Selection | 3 | 2009 | 4216 | 0.090 |
Why?
|
Lymph Node Excision | 3 | 2006 | 1262 | 0.090 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2014 | 1222 | 0.090 |
Why?
|
Hyperpigmentation | 1 | 2011 | 112 | 0.090 |
Why?
|
Mastectomy | 3 | 2015 | 1793 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2005 | 627 | 0.090 |
Why?
|
Anastomosis, Surgical | 3 | 2005 | 987 | 0.090 |
Why?
|
Electric Conductivity | 8 | 2001 | 411 | 0.090 |
Why?
|
Cell Line, Tumor | 18 | 2006 | 16690 | 0.090 |
Why?
|
Bacterial Infections | 2 | 2009 | 1401 | 0.090 |
Why?
|
Carboplatin | 5 | 2008 | 801 | 0.090 |
Why?
|
Gastric Acidity Determination | 1 | 1989 | 62 | 0.090 |
Why?
|
Feasibility Studies | 9 | 2016 | 5077 | 0.090 |
Why?
|
Food | 5 | 2010 | 772 | 0.090 |
Why?
|
Postmenopause | 3 | 2004 | 2460 | 0.090 |
Why?
|
Transcriptional Activation | 2 | 2013 | 1783 | 0.080 |
Why?
|
Neoplasms | 5 | 2010 | 21696 | 0.080 |
Why?
|
Isoenzymes | 4 | 2004 | 1728 | 0.080 |
Why?
|
Skin | 1 | 2002 | 4372 | 0.080 |
Why?
|
Skin Pigmentation | 1 | 2011 | 282 | 0.080 |
Why?
|
Mice, Nude | 9 | 2004 | 3689 | 0.080 |
Why?
|
Informed Consent | 1 | 2015 | 995 | 0.080 |
Why?
|
Infusions, Intravenous | 6 | 2007 | 2274 | 0.080 |
Why?
|
Glucose Intolerance | 1 | 2013 | 577 | 0.080 |
Why?
|
Neovascularization, Physiologic | 2 | 2008 | 1351 | 0.080 |
Why?
|
Immunohistochemistry | 7 | 2008 | 11366 | 0.080 |
Why?
|
Glucose Transporter Type 5 | 2 | 2005 | 13 | 0.080 |
Why?
|
Receptors, Progesterone | 2 | 2011 | 1098 | 0.080 |
Why?
|
Radiotherapy Dosage | 10 | 2006 | 2879 | 0.080 |
Why?
|
Microelectrodes | 6 | 1994 | 303 | 0.080 |
Why?
|
Tomography, Emission-Computed | 1 | 2011 | 1144 | 0.080 |
Why?
|
Stomach Ulcer | 2 | 1987 | 125 | 0.080 |
Why?
|
Necturus | 6 | 1987 | 14 | 0.080 |
Why?
|
Veterans | 1 | 2022 | 2519 | 0.080 |
Why?
|
Antineoplastic Agents | 9 | 2012 | 13693 | 0.080 |
Why?
|
Hospitals, Teaching | 3 | 2012 | 1180 | 0.080 |
Why?
|
MAP Kinase Signaling System | 2 | 2013 | 1525 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 941 | 0.080 |
Why?
|
Random Allocation | 3 | 2005 | 2428 | 0.080 |
Why?
|
Epithelial Cells | 3 | 2013 | 3690 | 0.080 |
Why?
|
Cerebral Angiography | 1 | 2014 | 1285 | 0.080 |
Why?
|
Splenic Neoplasms | 1 | 2008 | 100 | 0.080 |
Why?
|
Adolescent | 37 | 2017 | 85779 | 0.080 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2010 | 370 | 0.080 |
Why?
|
Thrombocytopenia | 2 | 2015 | 1178 | 0.080 |
Why?
|
Endothelins | 2 | 1998 | 138 | 0.080 |
Why?
|
Physician Incentive Plans | 1 | 2009 | 161 | 0.080 |
Why?
|
Sarcoma | 3 | 2010 | 1897 | 0.080 |
Why?
|
Thienamycins | 1 | 2007 | 28 | 0.080 |
Why?
|
Splenectomy | 2 | 2002 | 395 | 0.080 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2009 | 323 | 0.080 |
Why?
|
Academic Medical Centers | 4 | 2016 | 2760 | 0.080 |
Why?
|
Biopsy, Needle | 4 | 2005 | 1641 | 0.080 |
Why?
|
Keratins | 2 | 2006 | 515 | 0.080 |
Why?
|
Biological Clocks | 1 | 2010 | 322 | 0.080 |
Why?
|
Colitis, Ulcerative | 2 | 1998 | 1911 | 0.080 |
Why?
|
Portal Vein | 1 | 1990 | 437 | 0.080 |
Why?
|
Transcription, Genetic | 5 | 2008 | 7721 | 0.070 |
Why?
|
Acetates | 1 | 1989 | 311 | 0.070 |
Why?
|
Drug Tolerance | 1 | 2009 | 376 | 0.070 |
Why?
|
Tumor Cells, Cultured | 9 | 2004 | 6313 | 0.070 |
Why?
|
Receptors, Glucagon | 2 | 2004 | 92 | 0.070 |
Why?
|
World Health Organization | 2 | 2011 | 1318 | 0.070 |
Why?
|
HMGA Proteins | 1 | 2006 | 8 | 0.070 |
Why?
|
Focal Adhesion Kinase 1 | 5 | 2004 | 120 | 0.070 |
Why?
|
Sensory Receptor Cells | 1 | 2011 | 493 | 0.070 |
Why?
|
Transfection | 7 | 2012 | 5895 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2013 | 10943 | 0.070 |
Why?
|
Liver Neoplasms | 4 | 2010 | 4253 | 0.070 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 5 | 2004 | 182 | 0.070 |
Why?
|
Eating | 7 | 2008 | 1536 | 0.070 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2006 | 24 | 0.070 |
Why?
|
Muscle, Smooth | 2 | 2010 | 934 | 0.070 |
Why?
|
Respirovirus Infections | 1 | 2006 | 50 | 0.070 |
Why?
|
Video Recording | 1 | 2012 | 949 | 0.070 |
Why?
|
Antigens, CD | 10 | 2005 | 4026 | 0.070 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 2006 | 31 | 0.070 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 329 | 0.070 |
Why?
|
Catheterization, Peripheral | 1 | 1990 | 345 | 0.070 |
Why?
|
Chewing Gum | 1 | 2006 | 41 | 0.070 |
Why?
|
Bone Density | 2 | 1998 | 3468 | 0.070 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2006 | 57 | 0.070 |
Why?
|
Vascular Patency | 2 | 2000 | 887 | 0.070 |
Why?
|
Surgical Flaps | 1 | 2015 | 1640 | 0.070 |
Why?
|
Ileus | 1 | 2006 | 58 | 0.070 |
Why?
|
Medical Errors | 2 | 2011 | 1297 | 0.070 |
Why?
|
Sucrase | 3 | 2005 | 54 | 0.070 |
Why?
|
Platelet Activating Factor | 2 | 2001 | 149 | 0.070 |
Why?
|
Carbapenems | 1 | 2007 | 118 | 0.070 |
Why?
|
Language | 1 | 2015 | 1471 | 0.070 |
Why?
|
Nitric Oxide | 1 | 1995 | 2132 | 0.070 |
Why?
|
Transplantation, Isogeneic | 2 | 2004 | 257 | 0.070 |
Why?
|
Prostaglandins E, Synthetic | 1 | 1985 | 14 | 0.070 |
Why?
|
Gastric Outlet Obstruction | 1 | 2006 | 56 | 0.070 |
Why?
|
Risk Management | 2 | 2007 | 571 | 0.070 |
Why?
|
Ependymoma | 1 | 2009 | 334 | 0.070 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 1985 | 22 | 0.070 |
Why?
|
Fellowships and Scholarships | 2 | 2011 | 1078 | 0.070 |
Why?
|
Ion Transport | 2 | 1997 | 320 | 0.070 |
Why?
|
Hoarseness | 1 | 2006 | 65 | 0.070 |
Why?
|
Enterostomy | 1 | 2005 | 14 | 0.070 |
Why?
|
DNA | 5 | 2010 | 7294 | 0.070 |
Why?
|
Pilot Projects | 9 | 2016 | 8319 | 0.070 |
Why?
|
Leadership | 2 | 2012 | 1357 | 0.070 |
Why?
|
Neoplasm Transplantation | 6 | 2004 | 2086 | 0.070 |
Why?
|
Fibrinolytic Agents | 1 | 2015 | 2158 | 0.070 |
Why?
|
Endoscopy, Digestive System | 2 | 2001 | 345 | 0.070 |
Why?
|
Sensitivity and Specificity | 6 | 2012 | 14723 | 0.070 |
Why?
|
Colorectal Surgery | 1 | 2007 | 128 | 0.070 |
Why?
|
Neutropenia | 2 | 2009 | 895 | 0.070 |
Why?
|
RNA Transport | 1 | 2005 | 48 | 0.070 |
Why?
|
Cecum | 4 | 2001 | 237 | 0.060 |
Why?
|
Hospital Mortality | 3 | 2014 | 5316 | 0.060 |
Why?
|
Suicide | 1 | 2016 | 1474 | 0.060 |
Why?
|
Duodenal Neoplasms | 2 | 2003 | 106 | 0.060 |
Why?
|
Administration, Oral | 5 | 1999 | 3914 | 0.060 |
Why?
|
Dideoxyadenosine | 1 | 2004 | 6 | 0.060 |
Why?
|
Esophageal Diseases | 1 | 2006 | 167 | 0.060 |
Why?
|
Pancreatic Function Tests | 1 | 2005 | 69 | 0.060 |
Why?
|
MicroRNAs | 2 | 2012 | 3751 | 0.060 |
Why?
|
Attention | 1 | 2015 | 2397 | 0.060 |
Why?
|
Guidelines as Topic | 1 | 2011 | 1405 | 0.060 |
Why?
|
Cardia | 1 | 2004 | 57 | 0.060 |
Why?
|
Dinoprostone | 2 | 2004 | 601 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2008 | 3511 | 0.060 |
Why?
|
Disease Progression | 10 | 2011 | 13286 | 0.060 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2008 | 436 | 0.060 |
Why?
|
Secretin | 2 | 1995 | 57 | 0.060 |
Why?
|
Pertussis Toxin | 1 | 2004 | 178 | 0.060 |
Why?
|
Promoter Regions, Genetic | 3 | 2012 | 5867 | 0.060 |
Why?
|
Fractures, Bone | 1 | 1996 | 1947 | 0.060 |
Why?
|
Hospital Charges | 2 | 2011 | 362 | 0.060 |
Why?
|
Appendectomy | 1 | 2007 | 401 | 0.060 |
Why?
|
Logistic Models | 3 | 2016 | 13409 | 0.060 |
Why?
|
Bicarbonates | 3 | 1994 | 313 | 0.060 |
Why?
|
Suture Techniques | 2 | 2007 | 798 | 0.060 |
Why?
|
Diagnostic Techniques, Respiratory System | 1 | 2003 | 12 | 0.060 |
Why?
|
Mammography | 3 | 2009 | 2475 | 0.060 |
Why?
|
Teaching | 1 | 2012 | 1174 | 0.060 |
Why?
|
Body Mass Index | 2 | 2020 | 12721 | 0.060 |
Why?
|
Esophagoscopy | 1 | 2006 | 390 | 0.060 |
Why?
|
Intraoperative Complications | 1 | 2011 | 1198 | 0.060 |
Why?
|
Program Evaluation | 3 | 2018 | 2488 | 0.060 |
Why?
|
Myosin Type II | 1 | 2004 | 68 | 0.060 |
Why?
|
Methods | 3 | 1994 | 1129 | 0.060 |
Why?
|
Checklist | 1 | 2011 | 833 | 0.060 |
Why?
|
Caveolins | 1 | 2004 | 104 | 0.060 |
Why?
|
Rats, Zucker | 2 | 2014 | 128 | 0.060 |
Why?
|
Biliary Tract Diseases | 1 | 1985 | 161 | 0.060 |
Why?
|
Ki-67 Antigen | 3 | 2004 | 644 | 0.060 |
Why?
|
Minority Groups | 2 | 2022 | 1221 | 0.060 |
Why?
|
Mycoses | 1 | 2007 | 376 | 0.060 |
Why?
|
Unnecessary Procedures | 1 | 2007 | 432 | 0.060 |
Why?
|
Gastric Acid | 4 | 1988 | 104 | 0.060 |
Why?
|
Phlorhizin | 4 | 2008 | 37 | 0.060 |
Why?
|
Telemedicine | 1 | 2021 | 2872 | 0.060 |
Why?
|
Fibronectins | 2 | 2004 | 726 | 0.060 |
Why?
|
Comprehension | 1 | 2009 | 610 | 0.060 |
Why?
|
Withholding Treatment | 1 | 2008 | 599 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2064 | 0.060 |
Why?
|
Patient Discharge | 1 | 2016 | 3318 | 0.060 |
Why?
|
Integrin alphaVbeta3 | 1 | 2004 | 111 | 0.060 |
Why?
|
Disease Models, Animal | 8 | 2011 | 18034 | 0.060 |
Why?
|
Appendicitis | 2 | 2007 | 645 | 0.060 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1831 | 0.060 |
Why?
|
Vindesine | 2 | 1998 | 12 | 0.060 |
Why?
|
Pregnancy Complications | 2 | 2007 | 2861 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2017 | 19905 | 0.060 |
Why?
|
Carcinoma | 2 | 2010 | 2375 | 0.060 |
Why?
|
Physicians, Women | 1 | 2009 | 486 | 0.060 |
Why?
|
Nutritional Support | 1 | 2005 | 168 | 0.060 |
Why?
|
Enteral Nutrition | 3 | 2013 | 767 | 0.060 |
Why?
|
Splenic Vein | 1 | 2002 | 31 | 0.060 |
Why?
|
Hemangioma | 1 | 2008 | 738 | 0.060 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2003 | 146 | 0.060 |
Why?
|
Double-Blind Method | 8 | 2007 | 12025 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 6 | 2007 | 17446 | 0.060 |
Why?
|
Affective Symptoms | 1 | 2006 | 407 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 2016 | 0.050 |
Why?
|
Lymphangiogenesis | 1 | 2004 | 174 | 0.050 |
Why?
|
Fat Necrosis | 1 | 2002 | 58 | 0.050 |
Why?
|
Animal Nutritional Physiological Phenomena | 1 | 2002 | 57 | 0.050 |
Why?
|
Necturus maculosus | 3 | 1989 | 5 | 0.050 |
Why?
|
Light | 2 | 2010 | 1374 | 0.050 |
Why?
|
Inservice Training | 2 | 2018 | 392 | 0.050 |
Why?
|
Students, Medical | 2 | 2013 | 1862 | 0.050 |
Why?
|
Peptide Hormones | 1 | 2003 | 134 | 0.050 |
Why?
|
Growth Hormone | 2 | 2006 | 705 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 1995 | 1381 | 0.050 |
Why?
|
Organizational Innovation | 1 | 2006 | 559 | 0.050 |
Why?
|
Injections, Intravenous | 3 | 2000 | 1420 | 0.050 |
Why?
|
Microcirculation | 3 | 1996 | 1287 | 0.050 |
Why?
|
Amylases | 5 | 2001 | 173 | 0.050 |
Why?
|
Blood Loss, Surgical | 2 | 2011 | 662 | 0.050 |
Why?
|
Cough | 1 | 2006 | 555 | 0.050 |
Why?
|
Remission Induction | 5 | 2013 | 2385 | 0.050 |
Why?
|
Digestive System Diseases | 1 | 1984 | 147 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 1184 | 0.050 |
Why?
|
Gastroesophageal Reflux | 2 | 2007 | 782 | 0.050 |
Why?
|
Appendiceal Neoplasms | 1 | 2004 | 146 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2018 | 3677 | 0.050 |
Why?
|
Thyroid Neoplasms | 2 | 2010 | 2282 | 0.050 |
Why?
|
Craniopharyngioma | 2 | 1997 | 281 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2013 | 11726 | 0.050 |
Why?
|
Mother-Child Relations | 1 | 2006 | 481 | 0.050 |
Why?
|
Cholera Toxin | 1 | 2004 | 556 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 5 | 2005 | 4554 | 0.050 |
Why?
|
Blotting, Northern | 4 | 2005 | 1581 | 0.050 |
Why?
|
Transforming Growth Factors | 1 | 2001 | 76 | 0.050 |
Why?
|
Mitomycins | 5 | 2005 | 47 | 0.050 |
Why?
|
Obesity, Morbid | 1 | 2012 | 1213 | 0.050 |
Why?
|
Neutrophil Activation | 2 | 2001 | 186 | 0.050 |
Why?
|
Reference Values | 4 | 2011 | 4982 | 0.050 |
Why?
|
Nervous System Diseases | 2 | 2011 | 1622 | 0.050 |
Why?
|
Endarterectomy, Carotid | 1 | 2006 | 546 | 0.050 |
Why?
|
Amputation Stumps | 1 | 2001 | 39 | 0.050 |
Why?
|
Intestinal Fistula | 2 | 2000 | 140 | 0.050 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2003 | 599 | 0.050 |
Why?
|
Radiography, Interventional | 1 | 2009 | 1095 | 0.050 |
Why?
|
Lymphoma, B-Cell | 2 | 1998 | 931 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2003 | 433 | 0.050 |
Why?
|
Literature | 1 | 2001 | 16 | 0.050 |
Why?
|
Parent-Child Relations | 1 | 2006 | 747 | 0.050 |
Why?
|
Potassium | 5 | 2002 | 1336 | 0.050 |
Why?
|
Rhabdomyosarcoma | 1 | 2004 | 382 | 0.050 |
Why?
|
Prednisone | 3 | 2007 | 1574 | 0.050 |
Why?
|
Cell Membrane | 5 | 2005 | 3749 | 0.050 |
Why?
|
Sepsis | 3 | 2001 | 2593 | 0.050 |
Why?
|
Microspheres | 5 | 1987 | 777 | 0.050 |
Why?
|
Gene Targeting | 1 | 2004 | 880 | 0.050 |
Why?
|
Administration, Rectal | 1 | 2000 | 73 | 0.050 |
Why?
|
Piperacillin | 1 | 2000 | 41 | 0.050 |
Why?
|
Drainage | 2 | 2009 | 1142 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2014 | 3680 | 0.050 |
Why?
|
Rectal Neoplasms | 1 | 1990 | 1205 | 0.050 |
Why?
|
Child Behavior Disorders | 1 | 2006 | 807 | 0.050 |
Why?
|
Interprofessional Relations | 2 | 2021 | 1011 | 0.050 |
Why?
|
Lipase | 1 | 2002 | 314 | 0.050 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2007 | 868 | 0.050 |
Why?
|
Stereotyped Behavior | 1 | 2001 | 136 | 0.050 |
Why?
|
Platinum Compounds | 2 | 2011 | 96 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2009 | 1018 | 0.050 |
Why?
|
Radiography | 5 | 2009 | 7023 | 0.050 |
Why?
|
Cyclic AMP | 1 | 2004 | 1472 | 0.050 |
Why?
|
Weight Loss | 3 | 2012 | 2625 | 0.050 |
Why?
|
Parenteral Nutrition | 1 | 2005 | 650 | 0.050 |
Why?
|
Cranial Irradiation | 1 | 2003 | 401 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 4 | 2015 | 35425 | 0.050 |
Why?
|
Cohort Studies | 14 | 2013 | 40559 | 0.050 |
Why?
|
Mastectomy, Segmental | 3 | 2006 | 956 | 0.050 |
Why?
|
Up-Regulation | 4 | 2012 | 4222 | 0.050 |
Why?
|
Membrane Proteins | 4 | 2005 | 7882 | 0.040 |
Why?
|
Pancreaticojejunostomy | 1 | 1999 | 26 | 0.040 |
Why?
|
Minority Health | 1 | 2001 | 87 | 0.040 |
Why?
|
Indomethacin | 1 | 2000 | 332 | 0.040 |
Why?
|
Phantom Limb | 1 | 2001 | 91 | 0.040 |
Why?
|
Radiodermatitis | 1 | 2000 | 60 | 0.040 |
Why?
|
Skin Care | 1 | 2000 | 49 | 0.040 |
Why?
|
Stem Cell Transplantation | 2 | 2006 | 1620 | 0.040 |
Why?
|
Reperfusion Injury | 2 | 1997 | 1026 | 0.040 |
Why?
|
Leucine | 1 | 2001 | 560 | 0.040 |
Why?
|
Mexico | 1 | 2022 | 689 | 0.040 |
Why?
|
Epithelium | 5 | 1992 | 1679 | 0.040 |
Why?
|
Ligation | 2 | 2000 | 453 | 0.040 |
Why?
|
Bacterial Vaccines | 1 | 2002 | 403 | 0.040 |
Why?
|
Cytokines | 3 | 2007 | 7323 | 0.040 |
Why?
|
Hospitals, Rural | 1 | 2021 | 172 | 0.040 |
Why?
|
Hair Diseases | 1 | 2000 | 74 | 0.040 |
Why?
|
Membrane Transport Proteins | 1 | 2005 | 1031 | 0.040 |
Why?
|
Maltose | 1 | 1999 | 34 | 0.040 |
Why?
|
Antibodies, Neoplasm | 1 | 2000 | 286 | 0.040 |
Why?
|
Decision Trees | 1 | 2001 | 506 | 0.040 |
Why?
|
Absorption | 1 | 1999 | 248 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2006 | 9445 | 0.040 |
Why?
|
Tomography | 1 | 2001 | 390 | 0.040 |
Why?
|
Carcinoma in Situ | 1 | 2005 | 806 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2006 | 5172 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2007 | 1410 | 0.040 |
Why?
|
Neoplasm, Residual | 4 | 2006 | 973 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2004 | 692 | 0.040 |
Why?
|
Chest Pain | 1 | 2006 | 1114 | 0.040 |
Why?
|
Meningeal Neoplasms | 2 | 2002 | 1241 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 6539 | 0.040 |
Why?
|
Predictive Value of Tests | 6 | 2011 | 15078 | 0.040 |
Why?
|
Jaundice, Obstructive | 1 | 2018 | 20 | 0.040 |
Why?
|
Nursing Staff | 1 | 2000 | 129 | 0.040 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2005 | 852 | 0.040 |
Why?
|
Phosphorylation | 5 | 2013 | 8436 | 0.040 |
Why?
|
Malabsorption Syndromes | 2 | 1996 | 135 | 0.040 |
Why?
|
Norethindrone | 1 | 1998 | 59 | 0.040 |
Why?
|
Mannitol | 1 | 1999 | 181 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2015 | 25039 | 0.040 |
Why?
|
Enzyme Inhibitors | 3 | 2003 | 3799 | 0.040 |
Why?
|
Tunica Intima | 1 | 2000 | 464 | 0.040 |
Why?
|
Abdominal Abscess | 1 | 2000 | 154 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2007 | 4424 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 21748 | 0.040 |
Why?
|
Common Bile Duct | 2 | 2011 | 109 | 0.040 |
Why?
|
Bone Marrow Transplantation | 2 | 2001 | 2765 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2022 | 7785 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2012 | 3921 | 0.040 |
Why?
|
Evaluation Studies as Topic | 3 | 2012 | 1681 | 0.040 |
Why?
|
Faculty | 1 | 2021 | 387 | 0.040 |
Why?
|
Penicillins | 1 | 2000 | 380 | 0.040 |
Why?
|
Astrocytoma | 2 | 1993 | 790 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2004 | 8432 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3567 | 0.040 |
Why?
|
Tibial Arteries | 1 | 1997 | 57 | 0.040 |
Why?
|
Blood Flow Velocity | 2 | 2000 | 1423 | 0.040 |
Why?
|
Interleukin-1 | 2 | 2001 | 1263 | 0.040 |
Why?
|
Actuarial Analysis | 4 | 1999 | 378 | 0.040 |
Why?
|
Complement System Proteins | 1 | 2001 | 795 | 0.040 |
Why?
|
Protozoan Proteins | 1 | 2003 | 827 | 0.040 |
Why?
|
Base Sequence | 4 | 2003 | 12797 | 0.040 |
Why?
|
Quality of Life | 11 | 2005 | 12802 | 0.040 |
Why?
|
Placebos | 2 | 2006 | 1676 | 0.040 |
Why?
|
Hemorrhage | 2 | 2001 | 3461 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2002 | 794 | 0.040 |
Why?
|
Mucins | 1 | 2000 | 564 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12356 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2000 | 707 | 0.040 |
Why?
|
Scalp | 1 | 2000 | 380 | 0.040 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 5388 | 0.040 |
Why?
|
Femoral Vein | 1 | 1997 | 159 | 0.040 |
Why?
|
Age Factors | 9 | 2011 | 18373 | 0.040 |
Why?
|
Cross Infection | 1 | 2006 | 1417 | 0.040 |
Why?
|
Bleomycin | 1 | 1998 | 512 | 0.040 |
Why?
|
Emotional Intelligence | 1 | 2018 | 136 | 0.040 |
Why?
|
Vasopressins | 4 | 1987 | 370 | 0.040 |
Why?
|
Carbohydrates | 1 | 1999 | 394 | 0.040 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1997 | 179 | 0.040 |
Why?
|
Activities of Daily Living | 2 | 1997 | 2419 | 0.040 |
Why?
|
Heterozygote | 3 | 2007 | 2804 | 0.040 |
Why?
|
Burns | 1 | 2008 | 1815 | 0.040 |
Why?
|
Sex Factors | 3 | 2021 | 10400 | 0.040 |
Why?
|
Hair | 1 | 2000 | 481 | 0.040 |
Why?
|
Anticarcinogenic Agents | 1 | 1998 | 253 | 0.040 |
Why?
|
Cricetinae | 2 | 2012 | 2475 | 0.030 |
Why?
|
Prejudice | 1 | 2001 | 570 | 0.030 |
Why?
|
Macrophages | 3 | 2007 | 5660 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2010 | 2758 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2004 | 2016 | 0.030 |
Why?
|
Liver Diseases | 1 | 1985 | 1253 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2000 | 593 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2004 | 1741 | 0.030 |
Why?
|
Axilla | 3 | 2006 | 597 | 0.030 |
Why?
|
Leucovorin | 1 | 1998 | 628 | 0.030 |
Why?
|
Lymphedema | 1 | 2003 | 534 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2009 | 6489 | 0.030 |
Why?
|
Polymerase Chain Reaction | 4 | 2003 | 6171 | 0.030 |
Why?
|
Information Systems | 1 | 2018 | 410 | 0.030 |
Why?
|
Graft Survival | 2 | 2003 | 3737 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2008 | 5445 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2010 | 4034 | 0.030 |
Why?
|
Referral and Consultation | 2 | 2006 | 3531 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 2003 | 1678 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2011 | 9274 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 2958 | 0.030 |
Why?
|
Mice | 17 | 2007 | 81201 | 0.030 |
Why?
|
Burkitt Lymphoma | 1 | 1998 | 327 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2011 | 6234 | 0.030 |
Why?
|
Pyrimidines | 4 | 2012 | 2943 | 0.030 |
Why?
|
Kinetics | 3 | 2001 | 6476 | 0.030 |
Why?
|
Prostheses and Implants | 1 | 2003 | 1387 | 0.030 |
Why?
|
Perioperative Period | 1 | 2017 | 256 | 0.030 |
Why?
|
Insurance Selection Bias | 2 | 2007 | 67 | 0.030 |
Why?
|
Cerebrovascular Disorders | 1 | 2002 | 1504 | 0.030 |
Why?
|
Microvilli | 3 | 2002 | 241 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3773 | 0.030 |
Why?
|
Lymphoma, T-Cell | 1 | 1998 | 299 | 0.030 |
Why?
|
Endometrium | 1 | 1998 | 424 | 0.030 |
Why?
|
omega-N-Methylarginine | 1 | 1995 | 111 | 0.030 |
Why?
|
Colonoscopy | 2 | 2002 | 1367 | 0.030 |
Why?
|
Bronchoscopy | 1 | 2001 | 862 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2002 | 1149 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2003 | 3554 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2009 | 3086 | 0.030 |
Why?
|
Kidney | 1 | 2011 | 7184 | 0.030 |
Why?
|
Robotics | 1 | 2003 | 899 | 0.030 |
Why?
|
Age of Onset | 2 | 2004 | 3270 | 0.030 |
Why?
|
Calcium | 3 | 1993 | 5755 | 0.030 |
Why?
|
APACHE | 1 | 1995 | 277 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2000 | 1284 | 0.030 |
Why?
|
Imidazoles | 1 | 2001 | 1206 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2008 | 5023 | 0.030 |
Why?
|
Nitroprusside | 1 | 1995 | 275 | 0.030 |
Why?
|
Autoantibodies | 1 | 2003 | 2036 | 0.030 |
Why?
|
Software | 1 | 2009 | 4441 | 0.030 |
Why?
|
Multilingualism | 1 | 2015 | 87 | 0.030 |
Why?
|
Saccharin | 1 | 2014 | 20 | 0.030 |
Why?
|
Hydrochloric Acid | 2 | 2002 | 76 | 0.030 |
Why?
|
Amino Acid Oxidoreductases | 1 | 1995 | 151 | 0.030 |
Why?
|
Necrosis | 2 | 1996 | 1643 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2003 | 2441 | 0.030 |
Why?
|
Child | 17 | 2009 | 77709 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2015 | 520 | 0.030 |
Why?
|
Cause of Death | 3 | 2003 | 3582 | 0.030 |
Why?
|
Health Facility Size | 1 | 2014 | 64 | 0.030 |
Why?
|
Body Weight | 3 | 2011 | 4671 | 0.030 |
Why?
|
Translating | 1 | 2015 | 144 | 0.030 |
Why?
|
Blotting, Southern | 1 | 1995 | 803 | 0.030 |
Why?
|
Permeability | 1 | 1996 | 738 | 0.030 |
Why?
|
Organoplatinum Compounds | 2 | 2010 | 408 | 0.030 |
Why?
|
Survival | 1 | 1995 | 163 | 0.030 |
Why?
|
Nitrosourea Compounds | 1 | 1994 | 32 | 0.030 |
Why?
|
Personality | 1 | 2018 | 552 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 2282 | 0.030 |
Why?
|
Quality of Health Care | 3 | 2009 | 4369 | 0.030 |
Why?
|
Somatostatin | 1 | 1996 | 459 | 0.030 |
Why?
|
Adenocarcinoma, Follicular | 1 | 1998 | 324 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 4751 | 0.030 |
Why?
|
Advisory Committees | 1 | 2018 | 775 | 0.030 |
Why?
|
Stents | 2 | 1998 | 3282 | 0.030 |
Why?
|
New York | 2 | 2009 | 886 | 0.030 |
Why?
|
Skin Diseases | 1 | 2002 | 1066 | 0.030 |
Why?
|
Internal Medicine | 1 | 2021 | 1009 | 0.030 |
Why?
|
Dietetics | 1 | 2013 | 35 | 0.030 |
Why?
|
Enzyme Induction | 2 | 2004 | 475 | 0.030 |
Why?
|
Stereotaxic Techniques | 2 | 2009 | 536 | 0.030 |
Why?
|
Prebiotics | 1 | 2013 | 44 | 0.030 |
Why?
|
MEDLINE | 1 | 2013 | 125 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 2 | 2005 | 459 | 0.030 |
Why?
|
Solutions | 2 | 2002 | 426 | 0.030 |
Why?
|
Amino Acids | 2 | 2002 | 1737 | 0.030 |
Why?
|
Thiopental | 1 | 1993 | 59 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 1997 | 498 | 0.030 |
Why?
|
Pelvic Bones | 1 | 1996 | 265 | 0.030 |
Why?
|
Filgrastim | 2 | 2009 | 133 | 0.030 |
Why?
|
Respiratory Tract Infections | 1 | 2001 | 961 | 0.030 |
Why?
|
Maximum Tolerated Dose | 2 | 2009 | 892 | 0.030 |
Why?
|
Multiple Organ Failure | 2 | 2009 | 389 | 0.030 |
Why?
|
Mass Screening | 1 | 2009 | 5253 | 0.030 |
Why?
|
Absorptiometry, Photon | 2 | 1998 | 1725 | 0.030 |
Why?
|
Statistics, Nonparametric | 3 | 2006 | 2887 | 0.030 |
Why?
|
Cell Line | 4 | 2012 | 16000 | 0.030 |
Why?
|
Halothane | 1 | 1993 | 204 | 0.030 |
Why?
|
Colorectal Neoplasms | 2 | 2010 | 6773 | 0.030 |
Why?
|
Histamine | 2 | 1985 | 507 | 0.030 |
Why?
|
Pyrazoles | 1 | 2003 | 1972 | 0.030 |
Why?
|
Peroxidase | 3 | 2001 | 611 | 0.030 |
Why?
|
Molecular Sequence Data | 3 | 1995 | 18111 | 0.030 |
Why?
|
Neutrophils | 3 | 2001 | 3721 | 0.030 |
Why?
|
Benzamides | 2 | 2012 | 1379 | 0.030 |
Why?
|
Sodium Chloride | 2 | 2002 | 625 | 0.030 |
Why?
|
Patient Admission | 1 | 2000 | 1380 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2002 | 2073 | 0.030 |
Why?
|
Nutrition Therapy | 1 | 2013 | 96 | 0.030 |
Why?
|
Nitrous Oxide | 1 | 1993 | 176 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2003 | 1771 | 0.030 |
Why?
|
Thyroidectomy | 1 | 1998 | 879 | 0.030 |
Why?
|
Spinal Fractures | 1 | 1999 | 696 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2014 | 2971 | 0.030 |
Why?
|
Swine | 2 | 2007 | 5918 | 0.030 |
Why?
|
Cations, Divalent | 1 | 1992 | 166 | 0.030 |
Why?
|
Sensory System Agents | 1 | 2011 | 23 | 0.030 |
Why?
|
Lymph Nodes | 3 | 1999 | 3476 | 0.030 |
Why?
|
Outpatients | 1 | 2000 | 1487 | 0.030 |
Why?
|
Chlorambucil | 2 | 2007 | 43 | 0.030 |
Why?
|
Nitric Oxide Synthase | 1 | 1995 | 915 | 0.030 |
Why?
|
Transplantation, Heterologous | 3 | 2004 | 2383 | 0.030 |
Why?
|
Child, Preschool | 11 | 2009 | 41005 | 0.030 |
Why?
|
Procarbazine | 2 | 2007 | 181 | 0.030 |
Why?
|
Lactones | 2 | 2004 | 329 | 0.030 |
Why?
|
Sulfones | 2 | 2004 | 436 | 0.030 |
Why?
|
Oligopeptides | 1 | 1997 | 1189 | 0.030 |
Why?
|
Caspase 3 | 2 | 2004 | 758 | 0.030 |
Why?
|
Medicine | 2 | 2010 | 946 | 0.030 |
Why?
|
Cyclooxygenase 2 | 2 | 2004 | 612 | 0.030 |
Why?
|
Physician Executives | 1 | 2012 | 128 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2006 | 3508 | 0.030 |
Why?
|
Virginia | 1 | 2011 | 121 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2016 | 695 | 0.030 |
Why?
|
Workflow | 1 | 2016 | 847 | 0.030 |
Why?
|
Acupuncture Therapy | 1 | 1996 | 464 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2916 | 0.030 |
Why?
|
Resource Allocation | 1 | 2014 | 341 | 0.030 |
Why?
|
Sweetening Agents | 1 | 2014 | 296 | 0.030 |
Why?
|
Emphysema | 1 | 1994 | 247 | 0.020 |
Why?
|
Peer Review | 1 | 2013 | 209 | 0.020 |
Why?
|
Pyridines | 1 | 2003 | 2825 | 0.020 |
Why?
|
Ovarian Neoplasms | 2 | 2007 | 4839 | 0.020 |
Why?
|
Gene Expression | 4 | 2010 | 7798 | 0.020 |
Why?
|
Cells, Cultured | 4 | 2012 | 19233 | 0.020 |
Why?
|
Malignant Hyperthermia | 1 | 2011 | 73 | 0.020 |
Why?
|
Medicare | 3 | 2018 | 6566 | 0.020 |
Why?
|
Arginine | 1 | 1995 | 944 | 0.020 |
Why?
|
Wound Healing | 1 | 2002 | 2785 | 0.020 |
Why?
|
Ribosomal Proteins | 2 | 2003 | 360 | 0.020 |
Why?
|
Endosonography | 2 | 2007 | 610 | 0.020 |
Why?
|
Radiosurgery | 1 | 2001 | 1329 | 0.020 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 1990 | 25 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 925 | 0.020 |
Why?
|
Fractures, Spontaneous | 1 | 1993 | 230 | 0.020 |
Why?
|
Flow Cytometry | 3 | 2012 | 5974 | 0.020 |
Why?
|
Polyethylenes | 1 | 1993 | 285 | 0.020 |
Why?
|
Clinical Protocols | 2 | 2014 | 1461 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.020 |
Why?
|
Osteolysis | 1 | 1993 | 270 | 0.020 |
Why?
|
Cross-Linking Reagents | 2 | 2004 | 694 | 0.020 |
Why?
|
Embolism, Air | 1 | 2011 | 111 | 0.020 |
Why?
|
Electrophysiology | 2 | 2002 | 1308 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 2 | 1992 | 604 | 0.020 |
Why?
|
Anesthesia, Obstetrical | 1 | 1993 | 235 | 0.020 |
Why?
|
Rural Population | 1 | 2021 | 2207 | 0.020 |
Why?
|
Risk | 4 | 2011 | 9688 | 0.020 |
Why?
|
Comorbidity | 2 | 2018 | 10388 | 0.020 |
Why?
|
Cell Enlargement | 1 | 2010 | 61 | 0.020 |
Why?
|
Organizational Culture | 1 | 2014 | 510 | 0.020 |
Why?
|
Hydrocephalus | 1 | 1997 | 748 | 0.020 |
Why?
|
Disease Management | 1 | 2001 | 2460 | 0.020 |
Why?
|
Learning Curve | 1 | 2012 | 208 | 0.020 |
Why?
|
Cardiac Surgical Procedures | 1 | 2005 | 3537 | 0.020 |
Why?
|
Spinal Cord Neoplasms | 1 | 1993 | 281 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 2000 | 1352 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2000 | 2949 | 0.020 |
Why?
|
Algorithms | 4 | 2011 | 13882 | 0.020 |
Why?
|
Darkness | 1 | 2010 | 167 | 0.020 |
Why?
|
Probiotics | 1 | 2013 | 351 | 0.020 |
Why?
|
Diaphragm | 1 | 2011 | 349 | 0.020 |
Why?
|
Endoscopy | 1 | 2000 | 1787 | 0.020 |
Why?
|
Photoperiod | 1 | 2010 | 137 | 0.020 |
Why?
|
Dietary Fiber | 1 | 2013 | 760 | 0.020 |
Why?
|
Recombinant Proteins | 3 | 2009 | 6621 | 0.020 |
Why?
|
Foreign Medical Graduates | 1 | 2010 | 79 | 0.020 |
Why?
|
Thymidylate Synthase | 1 | 2009 | 75 | 0.020 |
Why?
|
Cell Survival | 3 | 2004 | 5882 | 0.020 |
Why?
|
Vision Disorders | 1 | 1997 | 1058 | 0.020 |
Why?
|
Karnofsky Performance Status | 2 | 2003 | 173 | 0.020 |
Why?
|
Islets of Langerhans | 1 | 1996 | 1352 | 0.020 |
Why?
|
Specialty Boards | 1 | 2011 | 227 | 0.020 |
Why?
|
Cell Proliferation | 3 | 2012 | 10483 | 0.020 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1990 | 417 | 0.020 |
Why?
|
Osteoporosis | 1 | 1999 | 1579 | 0.020 |
Why?
|
Quality Control | 1 | 2012 | 841 | 0.020 |
Why?
|
Pain | 2 | 2002 | 4988 | 0.020 |
Why?
|
Muscle, Skeletal | 2 | 2003 | 4925 | 0.020 |
Why?
|
New Jersey | 1 | 2009 | 290 | 0.020 |
Why?
|
Acetic Acid | 1 | 1989 | 55 | 0.020 |
Why?
|
Lymphocytes | 1 | 1997 | 2617 | 0.020 |
Why?
|
Carmustine | 1 | 1988 | 137 | 0.020 |
Why?
|
Iliac Artery | 1 | 1990 | 364 | 0.020 |
Why?
|
Organizational Policy | 1 | 2011 | 429 | 0.020 |
Why?
|
Reoperation | 1 | 1998 | 4201 | 0.020 |
Why?
|
GATA5 Transcription Factor | 1 | 2008 | 18 | 0.020 |
Why?
|
Health Services Research | 1 | 2016 | 1836 | 0.020 |
Why?
|
Professional Competence | 1 | 2012 | 447 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 1994 | 606 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1998 | 2865 | 0.020 |
Why?
|
Problem-Based Learning | 1 | 2012 | 361 | 0.020 |
Why?
|
Peutz-Jeghers Syndrome | 1 | 1988 | 50 | 0.020 |
Why?
|
Pennsylvania | 1 | 2009 | 613 | 0.020 |
Why?
|
Dyspnea | 1 | 1996 | 1303 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 94 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2009 | 9955 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2015 | 2453 | 0.020 |
Why?
|
Biopsy | 3 | 2009 | 6755 | 0.020 |
Why?
|
Animals, Newborn | 2 | 2003 | 2726 | 0.020 |
Why?
|
Cyclins | 1 | 2010 | 603 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1994 | 1275 | 0.020 |
Why?
|
Enzyme Activation | 2 | 2004 | 3702 | 0.020 |
Why?
|
Cell Movement | 3 | 2004 | 5218 | 0.020 |
Why?
|
Liver | 4 | 2000 | 7475 | 0.020 |
Why?
|
Piperazines | 2 | 2012 | 2488 | 0.020 |
Why?
|
Marriage | 1 | 2009 | 339 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2008 | 147 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2010 | 323 | 0.020 |
Why?
|
Aminopyrine | 1 | 1987 | 8 | 0.020 |
Why?
|
Transcription Factors | 2 | 2004 | 12207 | 0.020 |
Why?
|
Proto-Oncogenes | 1 | 1988 | 321 | 0.020 |
Why?
|
Nerve Fibers, Unmyelinated | 1 | 2008 | 98 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3873 | 0.020 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 1997 | 1391 | 0.020 |
Why?
|
Motivation | 2 | 2011 | 1971 | 0.020 |
Why?
|
Sodium Bicarbonate | 1 | 1987 | 62 | 0.020 |
Why?
|
Emergency Treatment | 1 | 2011 | 517 | 0.020 |
Why?
|
Interleukin-6 | 1 | 1997 | 3203 | 0.020 |
Why?
|
Radiation Injuries | 1 | 1994 | 1180 | 0.020 |
Why?
|
Cell Adhesion | 2 | 2004 | 3144 | 0.020 |
Why?
|
Hypercalcemia | 1 | 1990 | 409 | 0.020 |
Why?
|
Vagotomy, Proximal Gastric | 1 | 1986 | 8 | 0.020 |
Why?
|
Life Tables | 2 | 2000 | 370 | 0.020 |
Why?
|
Sucrose | 1 | 1987 | 164 | 0.020 |
Why?
|
Prevalence | 3 | 2010 | 15221 | 0.020 |
Why?
|
Ifosfamide | 2 | 1999 | 228 | 0.020 |
Why?
|
Medroxyprogesterone | 1 | 1986 | 37 | 0.020 |
Why?
|
Intra-Abdominal Fat | 1 | 2011 | 591 | 0.020 |
Why?
|
Transcription Factor RelA | 1 | 2007 | 275 | 0.020 |
Why?
|
Keratin-20 | 1 | 2006 | 31 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 1996 | 1848 | 0.020 |
Why?
|
Hepatectomy | 1 | 2010 | 550 | 0.020 |
Why?
|
Keratin-7 | 1 | 2006 | 57 | 0.020 |
Why?
|
Cricetulus | 1 | 2008 | 818 | 0.020 |
Why?
|
Depression | 1 | 2006 | 7759 | 0.020 |
Why?
|
Patient Compliance | 3 | 2007 | 2684 | 0.020 |
Why?
|
RNA | 2 | 2008 | 2749 | 0.020 |
Why?
|
Vagotomy, Truncal | 1 | 2005 | 9 | 0.020 |
Why?
|
Proteins | 2 | 2002 | 6100 | 0.020 |
Why?
|
Dactinomycin | 2 | 1999 | 318 | 0.020 |
Why?
|
Anesthesia, General | 1 | 1993 | 1171 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9849 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 1990 | 1401 | 0.020 |
Why?
|
Glycogen Synthase Kinases | 1 | 2005 | 40 | 0.020 |
Why?
|
Vascular Resistance | 2 | 1998 | 936 | 0.020 |
Why?
|
Quaternary Ammonium Compounds | 1 | 1986 | 205 | 0.020 |
Why?
|
Prolactinoma | 1 | 2006 | 113 | 0.020 |
Why?
|
Appointments and Schedules | 1 | 2009 | 417 | 0.020 |
Why?
|
Neurons, Afferent | 1 | 2008 | 506 | 0.020 |
Why?
|
Rupture, Spontaneous | 1 | 2006 | 354 | 0.020 |
Why?
|
Flurbiprofen | 1 | 1985 | 21 | 0.020 |
Why?
|
Pyrroles | 1 | 2012 | 1146 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1919 | 0.020 |
Why?
|
Gastritis | 1 | 1987 | 196 | 0.020 |
Why?
|
CHO Cells | 1 | 2008 | 1409 | 0.020 |
Why?
|
Urea | 1 | 1987 | 450 | 0.020 |
Why?
|
Hypertrophy | 1 | 2007 | 569 | 0.020 |
Why?
|
Genes, src | 1 | 2004 | 52 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1434 | 0.020 |
Why?
|
Ephrin-A1 | 1 | 2004 | 9 | 0.020 |
Why?
|
Bilirubin | 2 | 2000 | 425 | 0.020 |
Why?
|
Intercellular Junctions | 1 | 1985 | 203 | 0.020 |
Why?
|
Health Status | 2 | 2013 | 4034 | 0.020 |
Why?
|
Receptor, erbB-2 | 2 | 2006 | 2417 | 0.020 |
Why?
|
Swine, Miniature | 1 | 2007 | 961 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2002 | 10183 | 0.020 |
Why?
|
Physiology | 1 | 1985 | 115 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1856 | 0.020 |
Why?
|
Gastric Fundus | 1 | 1984 | 39 | 0.020 |
Why?
|
Vitronectin | 1 | 2004 | 44 | 0.020 |
Why?
|
Jaundice | 1 | 1985 | 89 | 0.020 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2004 | 66 | 0.020 |
Why?
|
Emergencies | 1 | 2011 | 1170 | 0.020 |
Why?
|
Partial Pressure | 1 | 1984 | 254 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 697 | 0.020 |
Why?
|
Cholangiography | 1 | 1985 | 189 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 3001 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1997 | 5096 | 0.020 |
Why?
|
Cesarean Section | 1 | 1993 | 1365 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 2 | 1999 | 228 | 0.020 |
Why?
|
Zollinger-Ellison Syndrome | 1 | 1984 | 15 | 0.020 |
Why?
|
Self Report | 1 | 2015 | 3553 | 0.020 |
Why?
|
Ovariectomy | 1 | 2007 | 661 | 0.020 |
Why?
|
Receptor, EphB3 | 1 | 2003 | 11 | 0.020 |
Why?
|
Propionates | 1 | 1985 | 169 | 0.020 |
Why?
|
Ribavirin | 1 | 2006 | 395 | 0.020 |
Why?
|
Electrodes | 2 | 2000 | 619 | 0.020 |
Why?
|
Eye Proteins | 1 | 2008 | 645 | 0.010 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2006 | 648 | 0.010 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 2004 | 76 | 0.010 |
Why?
|
Biliary Tract | 1 | 1985 | 134 | 0.010 |
Why?
|
Glucose Transporter Type 1 | 1 | 2004 | 193 | 0.010 |
Why?
|
Anaphylaxis | 1 | 2011 | 746 | 0.010 |
Why?
|
Quinones | 1 | 2003 | 76 | 0.010 |
Why?
|
Rifabutin | 1 | 2003 | 52 | 0.010 |
Why?
|
Vinculin | 1 | 2003 | 62 | 0.010 |
Why?
|
Inflammation | 3 | 2000 | 10637 | 0.010 |
Why?
|
Oncogene Protein v-akt | 1 | 2004 | 135 | 0.010 |
Why?
|
E2F1 Transcription Factor | 1 | 2004 | 190 | 0.010 |
Why?
|
Genistein | 1 | 2003 | 88 | 0.010 |
Why?
|
Mathematics | 1 | 1985 | 728 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2004 | 118 | 0.010 |
Why?
|
Lentivirus | 1 | 2006 | 503 | 0.010 |
Why?
|
Leiomyosarcoma | 1 | 1988 | 477 | 0.010 |
Why?
|
Cytochromes c | 1 | 2004 | 180 | 0.010 |
Why?
|
E2F Transcription Factors | 1 | 2004 | 277 | 0.010 |
Why?
|
Gastroscopy | 1 | 1985 | 207 | 0.010 |
Why?
|
Brunner Glands | 1 | 2003 | 11 | 0.010 |
Why?
|
Hyperemia | 1 | 1985 | 225 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2004 | 318 | 0.010 |
Why?
|
Indoles | 1 | 2012 | 1839 | 0.010 |
Why?
|
Patient Care | 1 | 2009 | 640 | 0.010 |
Why?
|
Alkaline Phosphatase | 2 | 2000 | 867 | 0.010 |
Why?
|
Nitrogen | 1 | 1984 | 344 | 0.010 |
Why?
|
Biopsy, Fine-Needle | 1 | 2008 | 1094 | 0.010 |
Why?
|
Pituitary Irradiation | 1 | 2002 | 17 | 0.010 |
Why?
|
Liver Function Tests | 1 | 1985 | 528 | 0.010 |
Why?
|
Omeprazole | 1 | 1984 | 112 | 0.010 |
Why?
|
Benzoquinones | 1 | 2003 | 201 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2009 | 1182 | 0.010 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2004 | 294 | 0.010 |
Why?
|
Phospholipids | 1 | 1987 | 784 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1342 | 0.010 |
Why?
|
Gallbladder Diseases | 1 | 1984 | 125 | 0.010 |
Why?
|
Parenteral Nutrition, Total | 1 | 1984 | 302 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 2003 | 288 | 0.010 |
Why?
|
Laminin | 1 | 2004 | 419 | 0.010 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2003 | 424 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8662 | 0.010 |
Why?
|
Leiomyoma | 1 | 1988 | 730 | 0.010 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2004 | 279 | 0.010 |
Why?
|
Health Services Accessibility | 2 | 2010 | 5135 | 0.010 |
Why?
|
Caveolin 1 | 1 | 2004 | 263 | 0.010 |
Why?
|
Neoplasm Proteins | 2 | 2006 | 3707 | 0.010 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2004 | 371 | 0.010 |
Why?
|
Isotonic Solutions | 2 | 1996 | 119 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2003 | 644 | 0.010 |
Why?
|
Thymidine | 1 | 2002 | 310 | 0.010 |
Why?
|
Luciferases | 1 | 2004 | 733 | 0.010 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2004 | 320 | 0.010 |
Why?
|
Myosin Light Chains | 1 | 2002 | 121 | 0.010 |
Why?
|
Interleukin-1beta | 1 | 2007 | 972 | 0.010 |
Why?
|
Receptor, IGF Type 1 | 1 | 2004 | 390 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2003 | 1157 | 0.010 |
Why?
|
Lactams, Macrocyclic | 1 | 2003 | 320 | 0.010 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 625 | 0.010 |
Why?
|
Cachexia | 1 | 2003 | 205 | 0.010 |
Why?
|
Tritium | 1 | 2002 | 745 | 0.010 |
Why?
|
Androstadienes | 1 | 2003 | 345 | 0.010 |
Why?
|
Cold Temperature | 1 | 2005 | 772 | 0.010 |
Why?
|
Retroviridae | 1 | 2004 | 914 | 0.010 |
Why?
|
Medical Audit | 1 | 2003 | 467 | 0.010 |
Why?
|
Soft Tissue Neoplasms | 1 | 1991 | 1363 | 0.010 |
Why?
|
Bile | 1 | 2002 | 299 | 0.010 |
Why?
|
Critical Care | 1 | 2014 | 2647 | 0.010 |
Why?
|
Prednisolone | 2 | 1993 | 334 | 0.010 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2003 | 224 | 0.010 |
Why?
|
3-O-Methylglucose | 1 | 2001 | 37 | 0.010 |
Why?
|
Transplants | 1 | 2003 | 209 | 0.010 |
Why?
|
Serine | 1 | 2005 | 826 | 0.010 |
Why?
|
Home Infusion Therapy | 1 | 2001 | 19 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2003 | 1095 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 2011 | 2269 | 0.010 |
Why?
|
Genes, Dominant | 1 | 2004 | 880 | 0.010 |
Why?
|
Infant | 5 | 2009 | 35134 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2006 | 2124 | 0.010 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2004 | 638 | 0.010 |
Why?
|
Guanosine | 1 | 2001 | 61 | 0.010 |
Why?
|
Esophagectomy | 1 | 2004 | 447 | 0.010 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1995 | 2428 | 0.010 |
Why?
|
Medicaid | 1 | 2014 | 2737 | 0.010 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2000 | 40 | 0.010 |
Why?
|
Physical Stimulation | 1 | 2002 | 525 | 0.010 |
Why?
|
Family Health | 1 | 2006 | 1281 | 0.010 |
Why?
|
Etoposide | 2 | 1993 | 641 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2013 | 3188 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1985 | 2031 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2008 | 2126 | 0.010 |
Why?
|
Cell Size | 1 | 2002 | 643 | 0.010 |
Why?
|
Benchmarking | 1 | 2007 | 1042 | 0.010 |
Why?
|
Mycobacterium | 1 | 2002 | 249 | 0.010 |
Why?
|
Mice, Inbred ICR | 1 | 2001 | 352 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1257 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2003 | 1799 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 2216 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2008 | 1070 | 0.010 |
Why?
|
Gastrectomy | 1 | 2004 | 663 | 0.010 |
Why?
|
Cell Count | 1 | 2004 | 1856 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2000 | 829 | 0.010 |
Why?
|
Fibrosis | 2 | 1999 | 2029 | 0.010 |
Why?
|
Bromodeoxyuridine | 1 | 2000 | 322 | 0.010 |
Why?
|
Phenols | 1 | 2003 | 497 | 0.010 |
Why?
|
Drug Synergism | 1 | 2004 | 1794 | 0.010 |
Why?
|
Consciousness | 1 | 1985 | 572 | 0.010 |
Why?
|
Syndrome | 1 | 2006 | 3252 | 0.010 |
Why?
|
Tyrosine | 1 | 2004 | 1462 | 0.010 |
Why?
|
Mammals | 1 | 2005 | 1143 | 0.010 |
Why?
|
Stress, Physiological | 1 | 1987 | 1403 | 0.010 |
Why?
|
Arteries | 1 | 1984 | 1119 | 0.010 |
Why?
|
Human Growth Hormone | 1 | 2004 | 683 | 0.010 |
Why?
|
Protein Transport | 1 | 2005 | 1988 | 0.010 |
Why?
|
Genes, ras | 1 | 2002 | 690 | 0.010 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2002 | 321 | 0.010 |
Why?
|
Drug Resistance, Viral | 1 | 2004 | 820 | 0.010 |
Why?
|
Carcinoembryonic Antigen | 1 | 2000 | 349 | 0.010 |
Why?
|
Diet | 2 | 2011 | 7937 | 0.010 |
Why?
|
Osmolar Concentration | 2 | 1992 | 683 | 0.010 |
Why?
|
Anxiety | 2 | 2004 | 4293 | 0.010 |
Why?
|
Tape Recording | 1 | 1998 | 76 | 0.010 |
Why?
|
Complement Activation | 1 | 2001 | 453 | 0.010 |
Why?
|
Infection Control | 1 | 2006 | 965 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2003 | 1950 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 2027 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2008 | 2418 | 0.010 |
Why?
|
Benzimidazoles | 1 | 1984 | 850 | 0.010 |
Why?
|
Family | 1 | 2009 | 3147 | 0.010 |
Why?
|
Electric Impedance | 1 | 2002 | 729 | 0.010 |
Why?
|
Punctures | 1 | 2000 | 374 | 0.010 |
Why?
|
Platinum | 1 | 2000 | 233 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2000 | 876 | 0.010 |
Why?
|
Pregnancy | 3 | 2007 | 29144 | 0.010 |
Why?
|
Ethionine | 1 | 1997 | 11 | 0.010 |
Why?
|
Life Style | 1 | 2009 | 3835 | 0.010 |
Why?
|
Choline Deficiency | 1 | 1997 | 28 | 0.010 |
Why?
|
Esophagus | 1 | 1984 | 1019 | 0.010 |
Why?
|
Respiration | 1 | 1984 | 1653 | 0.010 |
Why?
|
Insulin | 1 | 2012 | 6582 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2006 | 4777 | 0.010 |
Why?
|
Weight Gain | 1 | 2008 | 2293 | 0.010 |
Why?
|
Clonazepam | 1 | 1997 | 136 | 0.010 |
Why?
|
Glioblastoma | 2 | 1993 | 3481 | 0.010 |
Why?
|
DNA Primers | 1 | 2002 | 2891 | 0.010 |
Why?
|
Frozen Sections | 1 | 1998 | 155 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2004 | 1064 | 0.010 |
Why?
|
Organ Size | 1 | 2002 | 2251 | 0.010 |
Why?
|
Adolescent Behavior | 1 | 2006 | 1151 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2007 | 2795 | 0.010 |
Why?
|
Phenytoin | 1 | 1997 | 197 | 0.010 |
Why?
|
Mesenteric Artery, Superior | 1 | 1997 | 101 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2001 | 1892 | 0.010 |
Why?
|
Asparaginase | 1 | 1998 | 236 | 0.010 |
Why?
|
Busulfan | 1 | 1997 | 263 | 0.010 |
Why?
|
Abdomen, Acute | 1 | 1997 | 123 | 0.010 |
Why?
|
Lung | 3 | 2001 | 9857 | 0.010 |
Why?
|
Myositis Ossificans | 1 | 1997 | 79 | 0.010 |
Why?
|
Methylprednisolone | 1 | 1998 | 387 | 0.010 |
Why?
|
Devazepide | 1 | 1996 | 4 | 0.010 |
Why?
|
Lumbosacral Region | 1 | 1998 | 310 | 0.010 |
Why?
|
Receptors, Cholecystokinin | 1 | 1996 | 18 | 0.010 |
Why?
|
Telephone | 1 | 2000 | 617 | 0.010 |
Why?
|
Digestion | 1 | 1996 | 54 | 0.010 |
Why?
|
Benzodiazepinones | 1 | 1996 | 51 | 0.010 |
Why?
|
Cytarabine | 1 | 1998 | 692 | 0.010 |
Why?
|
Buffers | 1 | 1996 | 147 | 0.010 |
Why?
|
Infusions, Parenteral | 1 | 1996 | 419 | 0.010 |
Why?
|
Actins | 1 | 2004 | 2121 | 0.010 |
Why?
|
Sialoglycoproteins | 1 | 1997 | 318 | 0.010 |
Why?
|
Melphalan | 1 | 1997 | 431 | 0.010 |
Why?
|
Acupuncture Points | 1 | 1996 | 101 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2006 | 2943 | 0.010 |
Why?
|
Hormone Antagonists | 1 | 1996 | 108 | 0.010 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 1997 | 220 | 0.010 |
Why?
|
NF-kappa B | 1 | 2004 | 2499 | 0.010 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 1997 | 297 | 0.010 |
Why?
|
Cutaneous Fistula | 1 | 1995 | 78 | 0.010 |
Why?
|
Heart | 1 | 2009 | 4464 | 0.010 |
Why?
|
Perception | 1 | 2002 | 1198 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2004 | 2969 | 0.010 |
Why?
|
Enterobacter | 1 | 1994 | 46 | 0.010 |
Why?
|
Carcinoma, Large Cell | 1 | 1995 | 113 | 0.010 |
Why?
|
Endocrine Glands | 1 | 1994 | 103 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1996 | 577 | 0.010 |
Why?
|
Translocation, Genetic | 1 | 2000 | 1420 | 0.010 |
Why?
|
Professional-Patient Relations | 1 | 2000 | 737 | 0.010 |
Why?
|
Fistula | 1 | 1996 | 220 | 0.010 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 1994 | 113 | 0.010 |
Why?
|
Ribonucleases | 1 | 1995 | 287 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2004 | 2638 | 0.010 |
Why?
|
Retroperitoneal Neoplasms | 1 | 1997 | 340 | 0.010 |
Why?
|
Health Care Reform | 1 | 2003 | 1261 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16367 | 0.010 |
Why?
|
Streptococcus | 1 | 1994 | 197 | 0.010 |
Why?
|
Decompression, Surgical | 1 | 1999 | 594 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2002 | 1889 | 0.010 |
Why?
|
Neurosecretory Systems | 1 | 1995 | 231 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2006 | 2987 | 0.010 |
Why?
|
Anesthesia | 1 | 1985 | 1561 | 0.010 |
Why?
|
Blood Cell Count | 1 | 1994 | 403 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1994 | 919 | 0.010 |
Why?
|
Regeneration | 1 | 2002 | 1485 | 0.010 |
Why?
|
Computer Simulation | 1 | 2007 | 6194 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2000 | 934 | 0.010 |
Why?
|
Endometrial Neoplasms | 1 | 2003 | 1351 | 0.010 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 1997 | 484 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 1995 | 1375 | 0.010 |
Why?
|
Molecular Probes | 1 | 1995 | 316 | 0.010 |
Why?
|
Papaverine | 1 | 1992 | 46 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 1995 | 629 | 0.010 |
Why?
|
Glucagon | 1 | 1995 | 533 | 0.010 |
Why?
|
Serous Membrane | 1 | 1992 | 28 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2004 | 3464 | 0.010 |
Why?
|
Endocrine System Diseases | 1 | 1994 | 248 | 0.010 |
Why?
|
Mental Recall | 1 | 1998 | 1206 | 0.010 |
Why?
|
Feedback | 1 | 1996 | 795 | 0.010 |
Why?
|
Neurilemmoma | 1 | 1997 | 547 | 0.010 |
Why?
|
Patient Care Planning | 1 | 1997 | 921 | 0.010 |
Why?
|
Estrogen Replacement Therapy | 1 | 1998 | 1203 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1991 | 136 | 0.010 |
Why?
|
Bone Marrow Diseases | 1 | 1993 | 231 | 0.010 |
Why?
|
Nervous System | 1 | 1994 | 554 | 0.010 |
Why?
|
Menopause | 2 | 1991 | 1626 | 0.010 |
Why?
|
Spine | 1 | 1998 | 1144 | 0.010 |
Why?
|
Transplantation Conditioning | 1 | 1997 | 1599 | 0.010 |
Why?
|
Models, Cardiovascular | 1 | 1996 | 996 | 0.010 |
Why?
|
Aspartate Aminotransferases | 1 | 1992 | 418 | 0.010 |
Why?
|
Cost Control | 1 | 1993 | 624 | 0.010 |
Why?
|
Hydrocortisone | 1 | 1998 | 1826 | 0.010 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1994 | 652 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 1999 | 13991 | 0.010 |
Why?
|
Disability Evaluation | 1 | 1997 | 1828 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1988 | 18 | 0.010 |
Why?
|
Pressure | 1 | 1992 | 1203 | 0.010 |
Why?
|
Awareness | 1 | 1993 | 640 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2002 | 4479 | 0.010 |
Why?
|
Mutation | 2 | 2004 | 29786 | 0.010 |
Why?
|
Atrophy | 1 | 1993 | 1584 | 0.010 |
Why?
|
California | 1 | 1993 | 1402 | 0.010 |
Why?
|
Leukopenia | 1 | 1988 | 213 | 0.000 |
Why?
|
Reactive Oxygen Species | 1 | 1996 | 2076 | 0.000 |
Why?
|
Employment | 1 | 1994 | 1132 | 0.000 |
Why?
|
Tin | 1 | 1987 | 13 | 0.000 |
Why?
|
Anticonvulsants | 1 | 1997 | 1916 | 0.000 |
Why?
|
Potentiometry | 1 | 1987 | 10 | 0.000 |
Why?
|
Biological Transport, Active | 1 | 1987 | 349 | 0.000 |
Why?
|
Pentagastrin | 1 | 1986 | 17 | 0.000 |
Why?
|
Salts | 1 | 1987 | 65 | 0.000 |
Why?
|
Educational Status | 1 | 1994 | 2540 | 0.000 |
Why?
|
Stimulation, Chemical | 1 | 1986 | 326 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 9647 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1998 | 4459 | 0.000 |
Why?
|
Radioisotopes | 1 | 1987 | 500 | 0.000 |
Why?
|
Medroxyprogesterone Acetate | 1 | 1986 | 163 | 0.000 |
Why?
|
Radiotherapy | 1 | 1992 | 1533 | 0.000 |
Why?
|
Skin Neoplasms | 1 | 2004 | 5692 | 0.000 |
Why?
|
Seizures | 1 | 1997 | 2859 | 0.000 |
Why?
|
Mortality | 1 | 1996 | 2864 | 0.000 |
Why?
|
Aging | 1 | 2003 | 8664 | 0.000 |
Why?
|
Registries | 1 | 2000 | 8091 | 0.000 |
Why?
|
Capillary Permeability | 1 | 1988 | 798 | 0.000 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11126 | 0.000 |
Why?
|
Respiration Disorders | 1 | 1986 | 371 | 0.000 |
Why?
|
Emotions | 1 | 1994 | 2659 | 0.000 |
Why?
|
Edema | 1 | 1986 | 789 | 0.000 |
Why?
|
Gadolinium | 1 | 1987 | 952 | 0.000 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1988 | 948 | 0.000 |
Why?
|
Bone Marrow | 1 | 1988 | 2948 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1985 | 7914 | 0.000 |
Why?
|